# Pharmacokinetic and Pharmacodynamic Profiles of Aliskiren in Japanese Patients With Mild to Moderate Essential Hypertension

> **NCT00424541** · PHASE1 · COMPLETED · sponsor: **Novartis** · enrollment: 34 (estimated)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** SPP100 (aliskiren)

## Key facts

- **NCT ID:** NCT00424541
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-01
- **Primary completion:** —
- **Final completion:** 2007-08
- **Target enrollment:** 34 (ESTIMATED)
- **Last updated:** 2020-12-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00424541

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00424541, "Pharmacokinetic and Pharmacodynamic Profiles of Aliskiren in Japanese Patients With Mild to Moderate Essential Hypertension". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00424541. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*